Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00576251 · ClinicalTrials.gov registry record · Phase 3
TOBRADEX Ophthalmic Suspension Versus Tobramycin 0.3%/Dexamethasone 0.05% Ophthalmic Suspension
A Phase 3 study, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 3
- Development phase
- 221
- Enrollment target
NCT00576251 is a Phase 3 study that has completed, run by Alcon Research. The registered enrollment target is 221 participants.
The verdict
NCT00576251, a Phase 3 study, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 221 participants
- Enrollment target
Study Summary
The purpose of this study is to describe the differences in efficacy between TOBRADEX Ophthalmic Suspension and Tobramycin 0.3%/Dexamethasone 0.05% Ophthalmic Suspension in the treatment of ocular inflammation and infection associated with blepharaconjunctivitis
Interventions
- DRUG Tobramycin 0.3%/Dexamethasone 0.05%
- DRUG TOBRADEX
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 221 participants |
| Start Date | 2007-10 |
| Est. Completion | 2008-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00576251
The ClinicalTrials.gov registry entry for NCT00576251 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 221 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tobramycin 0.3%/Dexamethasone 0.05% is the first listed.
NCT00576251 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00576251 about?
NCT00576251 is a clinical study titled "TOBRADEX Ophthalmic Suspension Versus Tobramycin 0.3%/Dexamethasone 0.05% Ophthalmic Suspension". The purpose of this study is to describe the differences in efficacy between TOBRADEX Ophthalmic Suspension and Tobramycin 0.3%/Dexamethasone 0.05% Ophthalmic Suspension in the treatment of ocular inflammation and infection associated with blepharaconjunctivitis
What is the current status of trial NCT00576251?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 221 participants. The study started on 2007-10. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00576251?
The interventions under investigation include: Tobramycin 0.3%/Dexamethasone 0.05% (DRUG), TOBRADEX (DRUG).
Who is sponsoring clinical trial NCT00576251?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.